RPG Life Sciences Ltd

₹ 781 -1.43%
27 Jan - close price
About

RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.[1]
The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.[2] The group is headed by Harsh Goenka.[3]

Key Points

Domestic Formulations Segment (~62% of revenues)[1]
The company develops, manufactures and markets branded formulations in India & Nepal.[1] Its product portfolio includes various products which are sold under its key brands i.e. Azaron, Mofetyl, Lomitil, Arpimune, Imunotac, Serenace, etc. It launched 7 new products during FY21.
It has presence in various therapeutic segments such as nephrology, rheumatology, Oncology, Orthopaedics, Gastroenterology, and others.[2]

  • Market Cap 1,292 Cr.
  • Current Price 781
  • High / Low 1,013 / 451
  • Stock P/E 21.4
  • Book Value 168
  • Dividend Yield 1.23 %
  • ROCE 31.0 %
  • ROE 21.6 %
  • Face Value 8.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 29.6% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 27.8%
  • Debtor days have improved from 47.6 to 27.4 days.

Cons

  • The company has delivered a poor sales growth of 8.43% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
98 94 89 92 97 108 93 108 113 116 104 129 135
82 79 76 75 78 86 80 85 87 91 90 101 105
Operating Profit 16 15 12 17 19 21 13 23 26 24 14 28 30
OPM % 17% 16% 14% 18% 20% 20% 14% 21% 23% 21% 13% 22% 22%
0 0 -5 0 0 0 0 0 1 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 4 4 4 4 4 4 4 4 4 4 4 4 4
Profit before tax 12 10 3 13 15 17 9 19 22 21 11 25 27
Tax % 19% 24% 5% 29% 24% 25% 23% 30% 30% 29% 31% 28% 26%
Net Profit 10 8 3 9 11 13 7 14 16 15 8 18 20
EPS in Rs 5.91 4.78 1.80 5.48 6.74 7.78 4.18 8.21 9.52 8.85 4.55 11.01 12.07
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
187 193 222 236 242 279 294 344 330 376 389 440 483
154 175 206 224 228 256 274 306 296 315 318 353 388
Operating Profit 32 18 16 12 14 23 20 38 34 60 71 87 95
OPM % 17% 9% 7% 5% 6% 8% 7% 11% 10% 16% 18% 20% 20%
1 1 2 66 1 1 18 1 1 -5 1 3 4
Interest 6 7 7 3 3 2 4 5 5 3 2 1 0
Depreciation 10 10 10 11 11 10 11 14 15 16 16 16 15
Profit before tax 17 2 1 65 1 12 23 20 15 36 54 73 84
Tax % 27% 51% -717% 18% 0% 0% 10% 34% 28% 20% 25% 30%
Net Profit 13 1 4 53 1 12 21 13 11 29 40 51 60
EPS in Rs 7.69 0.51 2.67 32.29 0.60 7.03 12.70 8.13 6.54 17.54 24.19 31.13 36.48
Dividend Payout % 21% 156% 45% 6% 132% 23% 22% 30% 37% 23% 30% 31%
Compounded Sales Growth
10 Years: 9%
5 Years: 8%
3 Years: 10%
TTM: 15%
Compounded Profit Growth
10 Years: 50%
5 Years: 30%
3 Years: 67%
TTM: 23%
Stock Price CAGR
10 Years: 26%
5 Years: 9%
3 Years: 34%
1 Year: 31%
Return on Equity
10 Years: 12%
5 Years: 16%
3 Years: 21%
Last Year: 22%

Balance Sheet

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
13 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 62 61 63 113 112 120 134 142 147 163 203 243 265
53 54 63 15 33 23 45 54 36 12 2 1 0
62 54 67 56 39 49 55 82 54 78 85 88 96
Total Liabilities 189 183 206 196 197 205 247 291 251 267 303 345 374
112 109 103 106 105 109 137 131 128 123 113 104 107
CWIP 0 1 1 1 1 2 2 9 17 10 12 31 28
Investments 0 0 0 0 0 0 0 0 0 0 0 0 17
77 73 102 89 92 94 108 152 106 134 178 210 223
Total Assets 189 183 206 196 197 205 247 291 251 267 303 345 374

Cash Flows

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
14 16 12 -6 -2 33 7 15 46 50 58 65
-13 -8 -12 59 -10 -15 -30 -16 -19 -11 -8 -35
-2 -8 -0 -54 12 -18 23 0 -26 -39 -10 -14
Net Cash Flow -0 0 0 0 -0 -0 1 -1 0 0 40 17

Ratios

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 75 57 81 56 61 48 49 72 43 62 54 27
Inventory Days 193 190 140 180 149 156 163 171 136 133 162 214
Days Payable 293 161 226 176 109 135 102 165 83 127 132 117
Cash Conversion Cycle -24 86 -5 60 101 70 110 78 96 68 84 124
Working Capital Days 34 39 46 51 76 54 50 62 53 46 53 47
ROCE % 20% 7% 6% 2% 2% 9% 10% 13% 10% 23% 27% 31%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.07 72.41 72.62 72.62
0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.20 0.12 0.15 0.08 0.25
0.37 0.15 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.03 0.01
27.55 27.78 27.91 27.91 27.89 27.92 27.90 27.72 27.80 27.43 27.27 27.11

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls